Education
About Us
Working with TipRanks
Follow Us
BICO Group AB Class B (SE:BICO)
:BICO
BICO Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr23.82 - kr56.55
Previous CloseN/A
Volume245.45K
Average Volume (3M)372.73K
Market Cap
kr1.72B
Enterprise Valuekr3.32B
Total Cash (Recent Filing)kr596.50M
Total Debt (Recent Filing)kr1.41B
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Nov 04, 2025EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.54
Shares Outstanding69,074,900
10 Day Avg. Volume796,019
30 Day Avg. Volume372,733
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr36.05Price Target Upside50.21% Upside
Rating ConsensusHold
Number of Analyst Covering0
BICO Group AB Class B News
BICO FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was kr23.82 and its highest was kr56.55 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is kr1.72B.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Nov 04, 2025 which is in 67 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Aug 19, 2025. The company reported -kr2.54 earnings per share for the quarter, missing the consensus estimate of -kr1.2 by -kr1.34.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Undervalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.95.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -kr2.54 in its last earnings report, missing expectations of -kr1.2. Following the earnings report the stock price went down -22.725%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in SE:BICO
Company Description
BICO Group AB Class B
BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
BICO Company Deck
BICO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call presented a mixed picture of BICO's performance in Q2 2025. While the divestment of MatTek and Visikol significantly strengthened BICO's balance sheet, the company faced considerable challenges, particularly in the Lab Automation segment, with negative sales growth and profitability metrics. Macroeconomic conditions further impacted performance, introducing uncertainties and delayed investments. Despite strategic restructuring and operational improvements, negative trends outweighed positive developments.View all SE:BICO earnings summariesTechnical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
1.56% Other Institutional Investors
96.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---